JPWO2020252471A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020252471A5 JPWO2020252471A5 JP2021573797A JP2021573797A JPWO2020252471A5 JP WO2020252471 A5 JPWO2020252471 A5 JP WO2020252471A5 JP 2021573797 A JP2021573797 A JP 2021573797A JP 2021573797 A JP2021573797 A JP 2021573797A JP WO2020252471 A5 JPWO2020252471 A5 JP WO2020252471A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- residues
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025078346A JP2025121996A (ja) | 2019-06-14 | 2025-05-09 | Ｐｄ－１に対する抗体およびその使用方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962861643P | 2019-06-14 | 2019-06-14 | |
| US62/861,643 | 2019-06-14 | ||
| PCT/US2020/037781 WO2020252471A1 (en) | 2019-06-14 | 2020-06-15 | Antibodies against pd-1 and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025078346A Division JP2025121996A (ja) | 2019-06-14 | 2025-05-09 | Ｐｄ－１に対する抗体およびその使用方法 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022536370A JP2022536370A (ja) | 2022-08-15 |
| JP2022536370A5 JP2022536370A5 (https=) | 2023-06-21 |
| JPWO2020252471A5 true JPWO2020252471A5 (https=) | 2023-06-21 |
| JP7680967B2 JP7680967B2 (ja) | 2025-05-21 |
Family
ID=73781315
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021573797A Active JP7680967B2 (ja) | 2019-06-14 | 2020-06-15 | Ｐｄ－１に対する抗体およびその使用方法 |
| JP2025078346A Pending JP2025121996A (ja) | 2019-06-14 | 2025-05-09 | Ｐｄ－１に対する抗体およびその使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025078346A Pending JP2025121996A (ja) | 2019-06-14 | 2025-05-09 | Ｐｄ－１に対する抗体およびその使用方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20220275088A1 (https=) |
| EP (1) | EP3982997A4 (https=) |
| JP (2) | JP7680967B2 (https=) |
| AU (1) | AU2020290971A1 (https=) |
| CA (1) | CA3141628A1 (https=) |
| WO (1) | WO2020252471A1 (https=) |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2398076T3 (es) * | 2006-06-02 | 2013-03-13 | Regeneron Pharmaceuticals, Inc. | Anticuerpos de alta afinidad contra el receptor de IL-6 humano |
| US20100233154A1 (en) * | 2008-10-08 | 2010-09-16 | Medimmune Limited | Targeted binding agents directed to heparanase and uses thereof 463 |
| JO3182B1 (ar) * | 2009-07-29 | 2018-03-08 | Regeneron Pharma | مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2 |
| EP2284193A1 (en) * | 2009-08-10 | 2011-02-16 | Kenta Biotech AG | Human monoclonal antibody against S. aureus derived apha-toxin and its use in treating or preventing abscess formation |
| JP2014533659A (ja) * | 2011-10-24 | 2014-12-15 | アッヴィ・インコーポレイテッド | スクレロスチンに対するイムノバインダー |
| TWI681969B (zh) * | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| HK1254803A1 (zh) * | 2015-06-23 | 2019-07-26 | Memorial Sloan Kettering Cancer Center | 新型pd -1的免疫调节剂 |
| WO2017024515A1 (en) * | 2015-08-11 | 2017-02-16 | Wuxi Biologics (Cayman) Inc. | Novel anti-pd-1 antibodies |
| CN114605548A (zh) * | 2015-09-01 | 2022-06-10 | 艾吉纳斯公司 | 抗-pd-1抗体及其使用方法 |
| RU2656181C1 (ru) * | 2016-07-13 | 2018-05-31 | Закрытое Акционерное Общество "Биокад" | Анти-pd-1-антитела, способ их получения и способ применения |
| EP3497124A1 (en) * | 2016-08-12 | 2019-06-19 | ARSANIS Biosciences GmbH | Klebsiella pneumoniae o3 specific antibodies |
| US20230192839A1 (en) * | 2017-04-12 | 2023-06-22 | Pfizer Inc. | Antibodies having conditional affinity and methods of use thereof |
| US20200354460A1 (en) * | 2017-09-29 | 2020-11-12 | Wuxi Biologics Ireland Limited. | Bispecific antibodies against EGFR and PD-1 |
| WO2020113224A2 (en) * | 2018-11-30 | 2020-06-04 | Dana-Farber Cancer Institute, Inc. | Chimeric antigen receptor factories and methods of use thereof |
-
2020
- 2020-06-15 AU AU2020290971A patent/AU2020290971A1/en active Pending
- 2020-06-15 EP EP20822930.2A patent/EP3982997A4/en active Pending
- 2020-06-15 JP JP2021573797A patent/JP7680967B2/ja active Active
- 2020-06-15 WO PCT/US2020/037781 patent/WO2020252471A1/en not_active Ceased
- 2020-06-15 CA CA3141628A patent/CA3141628A1/en active Pending
- 2020-06-15 US US17/618,360 patent/US20220275088A1/en active Pending
-
2025
- 2025-05-09 JP JP2025078346A patent/JP2025121996A/ja active Pending